Patrick Daly

Urban Health Today

Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell maturation antigen (BCMA) approved for use in heavily pretreated patients with relapsed or refractory <a href="https://urbanhealthtoday.com/page/multiple-myeloma">multiple myeloma</a> (MM). In the open-label, phase 3 CARTITUDE-4 trial, researchers examined the effectiveness of cilta-cel as an earlier treatment line in patients refractory to lenalidomide.In the report published in The New England Journal of Medicine, the authors stated that a single infusion of cilta-cel yielded a lower risk of disease progression or death than standard of care.The <a href="https://www.nejm.org/doi/10.1056/NEJMoa2303379" target="_blank" rel="noopener">phase 3 trial</a> randomized 419 patients to either cilta-cel (n=208) or the physician&rsquo;s choice of effective standard care (n=211). All participants had received 1-3 prior lines of therapy.<h2>Cilta-Cel Improved Survival in Refractory MM</h2>Over a median follow-up of 15.9 months (range, 0.1-27.3), median progression-free survival (PFS) was not reached in the cilta-cel group and was 11.8 months in the standard of care group (hazard ratio [HR], 0.26; 95% CI, 0.18-0.38; P&lt;.001). The 12-month rates of PFS were 75.9% (95% CI, 69.4-81.1) and 48.6% (95% CI, 41.5-55.3) for cilta-cel and standard care, respectively.Compared with the standard-care group, more patients in the cilta-cel group had an overall response (84.6% vs 67.3%), a complete response or better (73.1% vs 21.8%), and an absence of minimal residual disease (60.6% vs 15.6%). Death from any cause occurred in 39 patients in the cilta-cel group and 46 in the standard care group (HR, 0.78; 95% CI, 0.5-1.2).In 176 patients who received cilta-cel in the as-treated population, 134 (76.1%) had cytokine release syndrome, 8 (4.5%) had immune effector cell-associated neurotoxicity syndrome, 1 had movement and neurocognitive symptoms, 16 (9.1%) had cranial nerve palsy, and 5 (2.8%) had CART-T-related peripheral neuropathy. The authors noted that most patients reported grade 3 or 4 adverse events during treatment.Overall, the authors suggested that cilta-cel may be effective in earlier lines of treatment among patients with refractory MM.Related: <a href="https://urbanhealthtoday.com/post/doacs-or-low-molecular-weight-heparin-for-vte-in-patients-with-cancer">DOACs or Low-Molecular-Weight Heparin for VTE in Patients With Cancer</a>

Lou Portero

Climate Change Is Loading Rice With Arsenic

Public Health

FDA Authorizes First Prescription Digital Therapeutic for Migraine Prevention

Women's Neurology

How Vagus Nerve Signals Affect Eating Habits Across Socioeconomic Lines

Obesity

Latest News

Cilta-Cel in Earlier Treatment Lines for Refractory Multiple Myeloma

Multiple Myeloma

Cilta-cel reportedly had lower rates of disease progression and death compared with standard care in patients with lenalidomide-refractory multiple myeloma.

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Autoimmune Disease

Infectious Diseases

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe